Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines.
Sensorium Therapeutics has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in August 2025.
Sensorium Therapeutics's investors include Sante Ventures, Hatteras Venture Partners, Mission BioCapital, Palo Santo Fund, Route 66 Ventures.
Sensorium Therapeutics is headquartered in Boston, United States.
Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines.
Sensorium Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sensorium Therapeutics — Funding & Investors." VCBacked, August 29, 2025, https://www.vcbacked.co/company/sensorium-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Sensorium Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/sensorium-therapeutics
{{cite web |title=Sensorium Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sensorium-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated